Clinical Trial Update: Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating docetaxel with or without suramin in second-line advanced non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Suramin (suramin)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Carcinoma, Non Small Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2020-05-12